Medtronic

2030 articles with Medtronic

• Mazor Robotics Shareholders Approve Merger Agreement With Medtronic

  11/19/2018

  Mazor Robotics Ltd. today announced that at a Special General Meeting of Shareholders held earlier today, Mazor Robotics shareholders approved the previously announced definitive merger agreement with wholly-owned subsidiaries of Medtronic plc (NYSE: MDT).

• Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2019

  11/9/2018

  Medtronic plc announced today that it will report financial results for the second quarter of fiscal year 2019 on Tuesday, November 20, 2018. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at http://newsroom.medtronic.com.

• Medtronic Delivers Significant Progress on Global Corporate Citizenship Efforts

  11/8/2018

  2018 Integrated Performance Report Shows Improvement on Environmental Stewardship and Diversity Aspirational Goals

• Medtronic Begins Renal Denervation Study for High Blood Pressure Patients Prescribed Anti-Hypertensive Medication

  11/8/2018

  FDA-Approved Study Furthers Medtronic Commitment to Generate Meaningful Clinical Evidence for Use of Renal Denervation to Treat Uncontrolled Hypertension

• Medtronic Presents IN.PACT SFA Trial Five-Year Data and Total IN.PACT All-Subjects Analysis in VIVA Late Breaking Clinical Trials

  11/6/2018

  New Data Continue to Reinforce IN.PACT Admiral DCB as a Durable, Frontline Option to Address Treatment Challenges in PAD

• FDA Approves New SynchroMed(TM) II myPTM(TM) Personal Therapy Manager That Enables Patients to Alleviate Unpredictable Pain

  10/24/2018

  myPTM Allows Patients to Personalize Their Treatment by Delivering On-Demand Boluses, or Drug Doses, Within Therapeutic Limits Set by Their Physician

• Medtronic Receives FDA Approval for Valiant Navion(TM) Thoracic Stent Graft System

  10/23/2018

  Next-Generation Thoracic Endovascular Repair (TEVAR) Device Expands Applicability to Broader Range of Patients

• Medtronic Co-Founder Earl Bakken Passes Away at Age 94

  10/21/2018

  Medtronic plc announced today that its co-founder, Earl E. Bakken, passed away peacefully on October 21, 2018 at his home on Kiholo Bay on the Big Island of Hawaii. He was 94 years old.

• Medtronic Launches the Control Workflow(SM) to Help Eliminate Oral Opioids and Provide Effective Pain Relief

  10/16/2018

  For Use with SynchroMed(TM) II Intrathecal Drug Delivery System, the Control WorkflowAims to Effectively Address Chronic Pain Without the Use of Oral Opioids

• 

  Thomson Reuters Report: 10 Biopharma Companies in Top 50 Most Diverse List

  9/29/2018

  Thomson Reuters recently announced their list of the top 100 most diverse and inclusive organizations. In the top 50 of the list there are 10 biopharma and medical device companies. Let’s take a look.

• Medtronic Launches the Infinity(TM) OCT Spinal System

  9/27/2018

  System is Fully Integrated with Medtronic's Market-Leading Imaging and Navigation Technology to Transform Posterior Cervical Spine Surgery

• MRI-guided Neurosurgical Ablation Market to Exceed A Value of US$ 216.3 Million During 2018 to 2028

  9/25/2018

  The global MRI-guided neurosurgical ablation market is projected to expand at a CAGR of 4.9% during the forecast period 2018–2028 and reach US$ 216.3 Mn by the end of 2028.

• 

  Medtronic Device Helps Paralyzed Patients Walk Again in Clinical Studies

  9/25/2018

  A commercially-available medical device developed by Medtronic is helping paralyzed patients walk again.The device, which stimulates the spinal cord through electrical pulses, has been successful in helping some individuals who lost the ability to walk through injuries to their spine, regain the ...

• Medtronic Builds on TAVR Clinical Evidence Portfolio with Five-Year CoreValve Durability Data and Complete Two-Year Outcomes in Intermediate Risk Aortic Stenosis Patients

  9/24/2018

  TCT18: New Five-Year Data with CoreValve TAVR System Suggests Durability Over Time, While Complete Results from the SURTAVI Trial Show Benefits of TAVR in Intermediate Risk Patients

• Late-Breaking Clinical Study Results Demonstrate Exceptional Safety and Efficacy Outcomes for Resolute Onyx(TM) DES

  9/22/2018

  TCT18: BIONYX Study Shows Strong Performance with Durable Polymer Resolute Onyx DES in Head-to-Head Comparison with Biodegradable Polymer DES

• Medtronic Presents IN.PACT Global Study Three-Year Data and Total IN.PACT(TM) Imaging and Propensity Analyses

  9/22/2018

  Clinical Evidence Shared at TCT and CIRSE Reaffirm IN.PACT(TM) Admiral(TM) Drug-Coated Balloon as a Primary Therapy to Treat Complex, Real-World Patient Populations

• Medtronic To Acquire Mazor Robotics

  9/21/2018

  Acquisition to Accelerate Medtronic's Strategy to Transform Spinal Procedures and Improve Outcomes Through Fully-Integrated Surgical Solutions

• Medtronic Announces Clinical Study of Transcatheter Aortic Valve Replacement in Aortic Stenosis Patients with Bicuspid Valves

  9/19/2018

  Medtronic Receives FDA Approval for Revised TAVR Labeling and Begins Investigational Study of Low Risk Patients with Bicuspid Valves

• Medtronic Joins Catalyst CEO Champions For Change and Pledges to Accelerate Women Into Management and Board Seats

  9/17/2018

  Medtronic CEO Omar Ishrak Commits to Continue Accelerating Diversity, Inclusion and Gender Equality

• Medtronic plc Recognized for Its Sustainability Leadership

  9/14/2018

  Company Marks its Eleventh Consecutive Year on the North American Dow Jones Sustainability Index (DJSI)